Reply  by Carabello, Blase A.
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s Quantitation a Good Value?
etaint et al. (1) show that averaging up to 3 quantitative
easures of aortic regurgitation (AR) provides prognostic
alue. They note that the association with mortality was
ignificant for quantitative measures (p  0.05), but not for
ualitative measures (p  0.15). Although the difference in
ortality prediction seems small, and could have been tested
irectly, it makes sense that quantitative measures are more
ccurate than qualitative ones. Dr. Carabello (2) bemoans the
imited use of quantitation by the community and ponders why
his might be. I suggest that clinicians and laboratory manag-
rs may question the value of quantitation.
Although the elegant study by Detaint et al. (1) gives us
vidence that quantitation has incremental benefit over qual-
tative reporting, the incremental cost to get this incremental
enefit is not described. Where does one reach flat-of-the-
urve value with quantitation? Would it not be even more
ccurate to average the measures of aortic regurgitation on
ach of 10 beats per patient taken on 3 different days? Detaint
t al. (1) could not be expected to address the cost effectiveness
f AR quantitation in the space allowed. However, their next
tep (and that of all who wish to promote any diagnostic
trategy) should be to test or model how the improvement in
ccuracy with a new diagnostic strategy can improve patient
utcome, and that any associated increase in cost is worth it to
atients and society.
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e thank Dr. Heidenreich for his interest in our Editorial
omment (1) and respond to his query about cost effective-
ess. I agree that we should have tested the cost effectiveness
f quantitative assessment of coronary stenoses and of accurate
easures of contractility long ago, and we did not. We still
ontinue to use 40-year-old techniques to manage coronary
isease, and one can only wonder how many needless stents qere placed or how many significant lesions were missed that
ould have been treated more effectively with the use of better
ools of assessment. That was the whole point of the editorial.
ow we have the chance to apply quantitative techniques to
alve disease. It would not seem to take many cases of aortic
nsufficiency poorly managed because of lesion misevaluation
nd the cost to society of those mistakes to prove cost
ffectiveness.
As with all cardiac evaluations, many lesions are so severe or
o trivial as not to require quantification. It is the lesions in the
iddle where 2 to 3 aortic regurgitation will never be good
nough for me or for my patients.
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e appreciate the comments of Dr. Heidenreich regarding
uantitative assessment of aortic regurgitation (AR) (1). Dr.
eidenreich suggests that clinicians and laboratory managers
ay question the value of quantitation and expresses concern
bout the cost involved.
The issue of cost is important and should always be a
reoccupation when it does not interfere with our ability to
are best for patients. We are not aware of a study on cost of
R evaluation and treatment. Thus, comments on increased
ost are conjectural and our practice argues to the contrary.
ndeed, the 10 to 15 min involved with AR quantitation may
ncrease the operating cost of echocardiography, reducing net
perative income somewhat, but there are other expenses to be
onsidered. In our practice, after AR quantitation, other tests
iming at AR severity assessment, such as repeat transthoracic
chocardiography, transesophageal echocardiography, or aor-
ography, are exceptionally required. The cost of any such test
ar exceeds the additional effort involved in quantitative
chocardiography, notwithstanding potential use of magnetic
esonance imaging. As an example of such a phenomenon, the
ecline in additional testing after quantitative valvular disease
ssessment has been well documented in aortic stenosis (2).
Dr. Heidenreich also raises the question of averaging
ultiple measurements made on multiple different days. Mak-
ng multiple measurements during the same examination is
uite simple with the current equipment and part of our
